ReviewFrontiers in medicine2026
An update on the diagnosis and treatment of seborrheic keratosis.
Review in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Seborrheic keratosis (SK) is a common benign epidermal neoplasm, particularly affecting the elderly. Although non-malignant, it often poses cosmetic and diagnostic challenges due to its resemblance to malignant skin tumors. This review aims to provide a comprehensive update on the recent advancements in the epidemiology, pathogenesis, diagnostic modalities, and therapeutic approaches for SK. Methods: A narrative review of current literature was conducted, focusing on molecular insights, diagnostic innovations, and therapeutic options for SK. Sources were identified through searches in PubMed, ScienceDirect, and Google Scholar over the last decade using relevant keywords. Result: Molecular research has highlighted the role of oncogenic mutations, including AKT pathway alterations and amyloid precursor protein (APP) involvement. Non-invasive diagnostic tools such as dermatoscopy, reflectance confocal microscopy (RCM), and optical coherence tomography (OCT) have improved lesion differentiation. Artificial intelligence (AI)-based algorithms have further enhanced diagnostic precision. While conventional therapies such as cryotherapy, excision, electrodesiccation, and laser remain effective, they may cause post-inflammatory hypopigmentation. Recent non-invasive treatments, including 30%-50% aqueous nitric-zinc oxide solution with organic acids, 65 or 80% trichloroacetic acid (TCA) solution, and 0.3% Annona muricata L. seed extract cream have demonstrated efficacy with minimal side effects. Nano-Pulse Stimulation (NPS) technology emerges as a novel low-complication treatment. Conclusion: Advances in molecular understanding and technology have transformed the diagnostic and therapeutic landscape for SK. There is a growing need for accessible, effective, and cosmetically favorable treatment options, especially with rising patient demand. Further research is warranted to validate long-term efficacy and broaden availability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.